Idiopathic Pulmonary Fibrosis

N Engl J Med. 2018 May 10;378(19):1811-1823. doi: 10.1056/NEJMra1705751.

Authors

David J Lederer¹, Fernando J Martinez¹

Affiliation

¹ From the Departments of Medicine and Epidemiology, Columbia University Irving Medical Center (D.J.L.), and the Department of Medicine, Weill Cornell Medical Center (F.J.M.) - both in New York.

PMID: 29742380
DOI: 10.1056/NEJMra1705751

No abstract available

Publication types

Review

MeSH terms

Diagnosis, Differential
Dyspnea / etiology
Enzyme Inhibitors / therapeutic use
Humans
Idiopathic Pulmonary Fibrosis* / diagnosis
Idiopathic Pulmonary Fibrosis* / drug therapy
Idiopathic Pulmonary Fibrosis* / physiopathology
Idiopathic Pulmonary Fibrosis* / therapy
Indoles / therapeutic use
Lung / diagnostic imaging*
Lung / pathology
Oxygen Inhalation Therapy
Prognosis
Pyridones / therapeutic use
Risk Factors
Tomography, X-Ray Computed
Transforming Growth Factor beta / antagonists & inhibitors

Substances

Enzyme Inhibitors
Indoles
Pyridones
Transforming Growth Factor beta
pirfenidone
nintedanib